Investor Relations

Investor Relations

Myriad Pharmaceuticals, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing novel small molecule drugs that address severe medical conditions, including cancer and HIV infection. Our pipeline includes clinical and pre-clinical product candidates with distinct mechanisms of action and novel chemical structures that have the potential to be first-in-class and/or best-in-class therapeutics.

Recent Releases

Feb 3, 2010
Myriad Pharmaceuticals to Present at BIO CEO & Investor Conference on February 8th

Feb 2, 2010
FDA Accepts Javelin Pharmaceuticals' Submission and Files New Drug Application for Dyloject(TM)

View all releases »

Events & Presentations

Feb 16, 2010
17th Conference on Retroviruses and Opportunistic Infections (CROI 2010)

Apr 17, 2010
AACR 101st Annual Meeting

View all events & presentations »

Stock Chart
Stock price graph
3 Mo.   6 Mo.   1 Yr.
Stock Quote
Myriad Pharmaceuticals, Inc.
Price: 4.20
Change: -0.07
Day High: 4.28
Day Low: 4.20
Volume: 111,700
Delayed at least 20 minutes.
Provided by eSignal.